|
|
 |
|
|
|
|
|
|
A Legacy of Excellence, A Future of Promise
|
|
|
|
In 2005, Schering-Plough Corporation solidified its historic commitment to the development of biologics by combining its two research sites in California to form
Schering-Plough Biopharma in Palo Alto, an integrated part of Schering-Plough Research Institute (SPRI). The laboratories of Canji, Inc., in San Diego, acquired in 1996, and Palo Alto-based DNAX Research Institute, acquired in 1982, joined together to focus resources on the discovery of novel monoclonal antibodies and therapeutic proteins. Together, these teams harness their strengths in inflammation and oncology research to move important biologic products into the clinic.
Built on a core facility model, Schering-Plough Biopharma’s R&D operations are fully integrated with Schering-Plough’s core pharmaceutical research and development organization to help assure a seamless and efficient overall product flow process.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About
Us
